Please login to the form below

Not currently logged in
Email:
Password:

GSK submits albiglutide for European approval

If approved the diabetes drug will be launched as Eperzan

GSK - logo on buildingGlaxoSmithKline (GSK) has submitted its albiglutide once-weekly injection for type 2 diabetes to European regulators.

If approved the biologic treatment, which was submitted for US approval in January, will be marketed as Eperzan.

Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

The diabetes treatment is a receptor agonist of the GLP-1 peptide, which is normally secreted from the gastrointestinal tract during a meal and in turn helps release insulin to control blood sugar elevations after eating. 

In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent and GSK said albiglutide has been developed to have a longer duration of action by being comprised of two copies of modified human GLP-1 fused in series to human albumin.

The diabetes treatment is in the same class as two established GLP-1 receptor agonists, Novo Nordisk's Victoza (liraglutide) and Lilly's Byetta (exenatide).

Albiglutide's phase III's trial programme, known as Harmony, includes studies that compare the drug's safety and efficacy to that of Victoza and Merck & Co's DPP-4 inhibitor Januvia (sitagliptin).

But the trial comparing GSK's drug with Victoza, the results of which were released in November 2011, failed to show that albiglutide was not inferior to Novo's rival drug.

GSK subsequently said that seven of the eight Harmony studies showed positive results and the company will be hoping that albiglutide's more favourable dosing regimen will give it an edge over its more established rivals.

8th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics